PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引:96
作者
Hirsch, Laure [1 ]
Zitvogel, Laurence [2 ]
Eggermont, Alexander [3 ]
Marabelle, Aurelien [1 ,2 ]
机构
[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France
[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France
关键词
OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;
D O I
10.1038/s41416-018-0294-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.
引用
收藏
页码:3 / 5
页数:3
相关论文
共 50 条
[21]   DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade [J].
Xue, Gang ;
Cui, Ze-Jia ;
Zhou, Xiong-Hui ;
Zhu, Yue-Xing ;
Chen, Ying ;
Liang, Feng-Ji ;
Tang, Da-Nian ;
Huang, Bing-Yang ;
Zhang, Hong-Yu ;
Hu, Zhi-Huang ;
Yuan, Xi-Yu ;
Xiong, Jianghui .
FRONTIERS IN GENETICS, 2019, 10
[22]   PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer [J].
Shankar, Bairavi ;
Naidoo, Jarushka .
JOURNAL OF THORACIC DISEASE, 2018, 10 :S4034-S4037
[23]   Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia [J].
Xing, Kai ;
Zhou, Pan ;
Li, Jiaojiao ;
Liu, Miao ;
Zhang, Wei Emma .
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2022, 25 (09) :1399-1410
[24]   Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer [J].
Tu, Megan M. ;
Ng, Terry L. ;
De Jong, Horns C. ;
Zuiverloon, Tahlita C. M. ;
Fazzari, Francesco G. T. ;
Theodorescu, Dan .
BLADDER CANCER, 2019, 5 (02) :131-145
[25]   PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer [J].
Bocanegra, Ana ;
Fernandez-Hinojal, Gonzalo ;
Zuazo-Ibarra, Miren ;
Arasanz, Hugo ;
Jesus Garcia-Granda, Maria ;
Hernandez, Carlos ;
Ibanez, Maria ;
Hernandez-Marin, Berta ;
Martinez-Aguillo, Maite ;
Jose Lecumberri, Maria ;
Fernandez de Lascoiti, Angela ;
Teijeira, Lucia ;
Morilla, Idoia ;
Vera, Ruth ;
Escors, David ;
Kochan, Grazyna .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
[26]   PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives [J].
Wang, Yumeng ;
Li, Guiling .
FRONTIERS OF MEDICINE, 2019, 13 (04) :438-450
[27]   PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer [J].
Hartkopf, Andreas D. ;
Taran, Florin-Andrei ;
Wallwiener, Markus ;
Walter, Christina B. ;
Kraemer, Bernhard ;
Grischke, Eva-Maria ;
Brucker, Sara Y. .
BREAST CARE, 2016, 11 (06) :385-390
[28]   Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment [J].
Wang, Qiaohong ;
Wu, Xia .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 46 :210-219
[29]   The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma [J].
Mahoney, Kathleen M. ;
Freeman, Gordon J. ;
McDermott, David F. .
CLINICAL THERAPEUTICS, 2015, 37 (04) :764-782
[30]   A novel combinatorial cancer immunotherapy poly-IC and blockade of the PD-1/PD-L1 pathway [J].
Nagato, Toshihiro ;
Celis, Esteban .
ONCOIMMUNOLOGY, 2014, 3 (05)